Collaboration to advance neuropilin-2 biology and explore potential therapeutic opportunities for ATYR1923 Reinforces aTyr’s commitment to working with a strategic network of leading academic collaborators SAN DIEGO , Jan. 30, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc.

Researchers from The Hong Kong University of Science and Technology credited with important translational science and early discovery work Significant opportunity to replicate collaborative model to develop pipeline of extracellular tRNA synthetase therapeutics SAN DIEGO and HONG KONG, Jan.

SAN DIEGO , Jan. 02, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that management will provide an update on the ongoing clinical

FSR Clinical Studies Network to assist with clinical site initiation to expedite patient enrollment SAN DIEGO , Dec. 04, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological

SAN DIEGO , Nov. 28, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that Sanjay Shukla , M.D., M.S., president and chief executive officer,

- Initiation of Proof-of-Concept Study in Patients with Pulmonary Sarcoidosis Planned for Fourth Quarter of 2018 -              - Conference Call Today at 5:00 p.m. ET / 2:00 p.m. PT – SAN DIEGO , Nov. 13, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged

SAN DIEGO , Nov. 08, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it will report its third quarter financial results on Tuesday,

SAN DIEGO , Oct. 17, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced a presentation at the American Society of Human Genetics 2018 Meeting in

SAN DIEGO , Oct. 15, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced the resignation of David J. King , Ph.D.

Conference Call and Webcast Featuring Leading Sarcoidosis Expert Dr. Daniel Culver on October 8, 2018 at 8:00 am ET SAN DIEGO , Sept. 27, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on